Tuesday, December 08, 2020 4:05:29 AM
Financials
RedHill has a market cap of approximately $330 million and a cash balance of $51 million. The company has not done a secondary offering in the recent past. Its cash burn is approximately $50 million, although this is really guesswork on my part. It appears that RedHill's existing cash reserves will last for a year, so expect a dilution or at least some non-dilutive financing if the company can manage it.
Bottom line
RedHill looks like a somewhat boring, long-term, relatively risk-free, low-headache investment for investors. Its 52-week range is $3.51-10.82, and the stock is currently trading at $8.82. The pandemic has been both good and bad for RedHill, because while it has halted most of the company’s efforts, this was also when the company made a radical shift in its focus and concentrated on developing its own products. Even a 5-year chart of the company looks relatively stale and uninteresting. If you want to add some anchor to your portfolio, this is a benign-looking investment at current prices.
RedHill has a market cap of approximately $330 million and a cash balance of $51 million. The company has not done a secondary offering in the recent past. Its cash burn is approximately $50 million, although this is really guesswork on my part. It appears that RedHill's existing cash reserves will last for a year, so expect a dilution or at least some non-dilutive financing if the company can manage it.
Bottom line
RedHill looks like a somewhat boring, long-term, relatively risk-free, low-headache investment for investors. Its 52-week range is $3.51-10.82, and the stock is currently trading at $8.82. The pandemic has been both good and bad for RedHill, because while it has halted most of the company’s efforts, this was also when the company made a radical shift in its focus and concentrated on developing its own products. Even a 5-year chart of the company looks relatively stale and uninteresting. If you want to add some anchor to your portfolio, this is a benign-looking investment at current prices.
Recent RDHL News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/14/2026 11:00:07 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 05:14:09 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/05/2026 02:00:19 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/25/2026 12:01:02 PM
- Joint U.S. Commercialization of RedHill's Talicia® Commences • PR Newswire (US) • 02/25/2026 12:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/02/2026 12:00:34 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/27/2026 12:00:58 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/22/2026 09:06:45 PM
- Form F-1/A - Registration statement for certain foreign private issuers: [Amend] • Edgar (US Regulatory) • 01/22/2026 09:04:43 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/22/2026 01:56:03 PM
- RedHill Biopharma Shares Jump on Progress Toward Treating GLP-1 Side Effects • IH Market News • 01/05/2026 02:59:05 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/05/2026 12:02:00 PM
- RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects • PR Newswire (US) • 01/05/2026 12:00:00 PM
- Form F-1 - Registration statement for certain foreign private issuers • Edgar (US Regulatory) • 12/31/2025 10:09:48 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/31/2025 09:58:07 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/23/2025 12:00:39 PM
